Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering
PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional...
Toggle Summary Agile Therapeutics Announces $4.85 Million Registered Direct Offering
PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell...
Toggle Summary Agile Therapeutics to Participate in Upcoming March Investor Events
PRINCETON, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will participate in two upcoming investor conferences, including a live panel discussion on drug...
Toggle Summary Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2021 financial results after the market close on Wednesday, March...
Toggle Summary Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost
PRINCETON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports women’s access to U.S. Food and Drug Administration (FDA) approved contraceptive products....
Toggle Summary Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
PRINCETON, N.J. and CHARLESTON, S.C., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced a new alliance with Afaxys Pharma, LLC to promote Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system....
Toggle Summary Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022, and at...
Toggle Summary Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30...
Toggle Summary Agile Therapeutics Reports Third Quarter 2021 Financial Results
Prescription Demand Growth Continues in the Third Quarter 2021 with a 61% Increase in Twirla Cycles Dispensed Twirla Refill Rates Continue to Grow by 86% in Third Quarter 2021 Company Advances Programs Focused on Increasing Demand for Twirla Management to Host Conference Call Today, Tuesday,...
Toggle Summary Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report third quarter 2021 financial results after the market close on Tuesday, November 2, 2021 as...
Shadow